Genetic Calcium Channel Blocking Therapy

Peak revenue. This figure is an explicitly hypothetical cohort-consistency placeholder, NOT a defensible product forecast — the asset is classified grant_non_commercial and the rNPV is not the decision criterion. If a modernized AAV version ever reached market for AF ventricular rate control, it would be a one-time therapy competing against ~$4/month generic rate-control drugs and a reimbursed AV-node-ablation-plus-pacemaker pathway on a symptomatic (non-mortality) endpoint; realistic uptake would be confined to a small refractory/device-averse niche. The placeholder is set well below cardiac-orphan-gene-therapy peaks because there is no orphan population, no pricing-power biomarker, and an entrenched cheap standard of care. The honest value path is academic licensing of the focal gene-modulation method / continued non-commercial research funding, not standalone product revenue.

WACC. A 22-year-old preclinical adenoviral proof-of-concept requiring full modern-vector reconstruction, in an indication where the only analogous cardiac Ca2+-handling gene therapy failed Phase 2b, sits well above mainstream-pharma risk and at the high end of the cardiac gene-therapy range.

This asset (JHU C04144) is the 2004 Murata/Donahue/Marbán proof-of-concept that adenoviral overexpression of the RGK-family GTPase Gem suppresses the cardiac L-type calcium current by sequestering the Cav-beta subunit — a "genetic calcium channel blocker." The demonstrated biology is real but is a basic-science / early enabling-method finding, not a development candidate: it was shown in guinea-pig ventricle and porcine AV node (slowing AV conduction for ventricular rate control in atrial fibrillation), published in Circ Res 2004;95:398-405, and the JHU listing still flags it Pre-Clinical 22 years later. It is honestly classified grant_non_commercial — the rNPV is not the decision criterion here, which is why the asset is classified grant_non_commercial; the rNPV envelope below is shown only for cohort consistency. The value path is academic licensing of the focal gene-modulation method or continued non-commercial research funding, not standalone product economics.

No true mechanism comparator exists in the clinic, so the economics are anchored to the nearest real archetype — cardiac AAV gene therapy — and that archetype is cautionary, not bullish: MYDICAR (AAV1/SERCA2a, the most analogous cardiac Ca2+-handling gene therapy) had FDA Breakthrough designation and positive early data yet failed Phase 2b CUPID-2 on every endpoint and the company dissolved; Rocket/Tenaya cardiac AAV programs are only now in Phase 1 (with Rocket's RP-A501 on a 2025 FDA clinical hold after a serious adverse event); and the leading dedicated AF gene-therapy effort, Rhythm Therapeutics, is still NIH-SBIR preclinical with a different mechanism. The engine result is -$54.7M to -$30.5M, with a base rNPV of -$42.6M and cumulative PoS of 2.0%; that spread is an illustrative placeholder, not a forecast — any modern AAV revectorization of this concept would compete against ~$4/month generic rate-control drugs and a reimbursed AV-node-ablation-plus-pacemaker pathway on a non-mortality endpoint, capping commercial relevance.

Verdict: a mechanistically elegant, well-cited but stale preclinical method whose rubric rank (composite 0.61) is driven by a high gene-therapy modality_pos and a neutral 0.5 "other"-indication whitespace plus high IRA exposure — not by being a fundable product. It earns its mid-pack slot on modality and clinical-relevance signal, and the honest archetype is grant_non_commercial because there is no orphan population, no biomarker pricing power, an entrenched cheap standard of care, and a 22-year IND-enabling gap.